Nathan N. Clumeck

Q: What Schools Are Affiliated With Nathan N. Clumeck

Nathan N. Clumeck is affiliated with the following schools: Vrije Universiteit Brussel

Nathan N. Clumeck's AcademicInfluence.com Rankings

Nathan N. Clumeck

Philosophy

#9211

World Rank

#12737

Historical Rank

Logic

#6200

World Rank

#7690

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Nathan N. Clumeck's Degrees

Bachelors Biology University of California, Berkeley
Doctorate Medicine University of California, San Francisco
Masters Public Health University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Nathan N. Clumeck Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nathan N. Clumeck's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection (2006) (3117)
CD4+ count-guided interruption of antiretroviral treatment. (2006) (1832)
Maraviroc for previously treated patients with R5 HIV-1 infection. (2008) (744)
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. (2013) (675)
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. (2005) (410)
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults (2008) (393)
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. (2020) (335)
ISOLATION OF AIDS VIRUS FROM CELL-FREE BREAST MILK OF THREE HEALTHY VIRUS CARRIERS (1985) (328)
ACQUIRED IMMUNODEFICIENCY SYNDROME IN RWANDA (1984) (327)
A controlled trial of zidovudine in primary human immunodeficiency virus infection. (1995) (324)
Acquired immunodeficiency syndrome in African patients. (1984) (299)
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study (2014) (286)
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. (2010) (278)
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. (1993) (266)
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study (2007) (255)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection (2009) (236)
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. (1996) (232)
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. (1993) (220)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression (2015) (216)
FEMALE PROSTITUTES: A RISK GROUP FOR INFECTION WITH HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III (1985) (207)
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml (2010) (205)
COMPARISON OF FLUCONAZOLE AND KETOCONAZOLE FOR OROPHARYNGEAL CANDIDIASIS IN AIDS (1989) (202)
ACQUIRED IMMUNE DEFICIENCY SYNDROME IN BLACK AFRICANS (1983) (199)
European guidelines for the clinical management and treatment of HIV-infected adults in Europe. (2003) (195)
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients (2003) (190)
Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing (2004) (185)
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients : A randomized controlled comparison with zidovudine monotherapy (1996) (180)
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA (2001) (167)
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. (2012) (162)
Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) (2013) (158)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016) (155)
Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140) (2007) (153)
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. (1999) (151)
The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003 (2004) (149)
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). (1994) (149)
Human immunodeficiency virus transmission among heterosexual couples in Central Africa. (1988) (146)
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies (2010) (146)
HIV and Syphilis: When to Perform a Lumbar Puncture (2007) (139)
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. (2009) (134)
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results (2016) (133)
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. (2016) (133)
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. (2003) (131)
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients (2012) (128)
Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma (1996) (126)
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing (2014) (112)
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen (2007) (104)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. (2001) (101)
Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff (2020) (100)
The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline (2012) (95)
Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. (1995) (95)
TRIZAL study: switching from successful HAART to TrizivirTM (abacavir‐lamivudine‐zidovudine combination tablet): 48 weeks efficacy, safety and adherence results (2003) (92)
Survival differences in European patients with AIDS, 1979–89 (1994) (89)
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. (2006) (89)
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. (2006) (87)
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS‐related complex: a double‐blind, randomized trial (1993) (83)
A cluster of HIV infection among heterosexual people without apparent risk factors. (1989) (82)
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. (2014) (82)
When should antiretroviral therapy for HIV be started? (2007) (79)
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine (1994) (78)
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine (1994) (78)
Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death (2007) (76)
Is nasogastric suction necessary in acute pancreatitis? (1978) (72)
Seroepidemiological studies of HTLV-III antibody prevalence among selected groups of heterosexual Africans. (1985) (71)
Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily (2005) (71)
A LOW T3 SYNDROME IN DIABETIC KETOACIDOSIS (1978) (70)
Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1 (2015) (70)
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double‐blind placebo‐controlled study (1994) (69)
A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome in Africa. (1985) (69)
Effect of Baseline CD4 Cell Count on the Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients With HIV/Hepatitis C Virus Coinfection (2008) (68)
Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study (2015) (66)
Meningoradiculoneuritis due to acyclovir‐resistant varicella zoster virus in an acquired immune deficiency syndrome patient (1994) (64)
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. (2011) (63)
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. (2012) (63)
Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. (1997) (62)
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. (2013) (60)
Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group. (1996) (58)
Rising Prevalence of HIV-1 Non-B Subtypes in Belgium: 1983–2001 (2004) (56)
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. (2007) (55)
Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study (2011) (55)
Clinical value of FDG-PET/CT for the diagnosis of human immunodeficiency virus-associated fever of unknown origin: a retrospective study (2009) (54)
Indicator disease‐guided testing for HIV – the next step for Europe? (2008) (53)
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. (2008) (52)
Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection (2006) (52)
A new topical treatment for resistant herpes simplex infections. (1993) (51)
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study (2016) (49)
Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. (1995) (48)
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial (2005) (48)
Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection (1996) (47)
Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. (2008) (45)
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. (2012) (45)
AFRICAN SWINE FEVER VIRUS ANTIBODY NOT FOUND IN AIDS PATIENTS (1983) (44)
Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. (1988) (44)
Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection (2007) (43)
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. (1994) (43)
Treatment of severe staphylococcal infections with a rifampicin-minocycline association. (1984) (42)
HIV-Associated Multinucleated Giant Cells in Lymphoid Tissue of the Waldeyer's Ring: A Detailed Study (2000) (41)
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. (2008) (40)
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. (2000) (39)
A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial (2005) (39)
Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients (2004) (39)
Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral Therapy (2002) (39)
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? (2008) (38)
Pancreatic disturbances and typhoid fever. (1991) (37)
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. (2012) (35)
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings (2014) (34)
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. (2013) (33)
Down regulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load (2011) (32)
ANTIBODY TO HTLV-III IN BLOOD DONORS IN CENTRAL AFRICA (1985) (31)
Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials (2014) (30)
Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line (2016) (30)
The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex (1991) (29)
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. (1999) (29)
High-risk human papillomavirus infection in HIV-positive African women living in Europe (2013) (29)
Efficacy and Safety of Trazodone versus Clorazepate in the Treatment of HIV-Positive Subjects with Adjustment Disorders: A Pilot Study (1999) (28)
HIV testing history and access to treatment among migrants living with HIV in Europe (2018) (28)
Effect of Fluconazole on Indinavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Patients (1998) (28)
Health-Related Quality of Life With Enfuvirtide (ENF; T-20) in Combination With an Optimized Background Regimen (2004) (27)
Sweet's syndrome in an HIV-infected patient. (1999) (27)
Efficacy and Safety of a Once-Daily Fixed-Dose Combination of Abacavir/Lamivudine Compared With Abacavir Twice Daily and Lamivudine Once Daily as Separate Entities in Antiretroviral-Experienced HIV-1-Infected Patients (CAL30001 Study) (2006) (27)
Choosing the best initial therapy for HIV-1 infection. (1999) (25)
Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching from HAART to Trizivir™ Versus Continued HAART: The Trizal Study (2003) (25)
AIDS-related Kaposi's sarcoma patients with visceral manifestations. Response to human chorionic gonadotropin preparations. (1998) (25)
Primary prophylaxis against opportunistic infections in patients with AIDS. (1995) (25)
HPV and HIV coinfection: a complex interaction resulting in epidemiological, clinical and therapeutic implications (2013) (24)
Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. (2010) (24)
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysis (2013) (24)
AIDS and associated cancers in Africa. (1988) (24)
Amoxicillin Entry into Human Cerebrospinal Fluid: Comparison with Ampicillin (1978) (23)
Primary infection with zidovudine-resistant HIV. (1993) (22)
Bovine leukemia virus-related antigens in lymphocyte cultures infected with AIDS-associated viruses. (1985) (22)
Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study (2016) (22)
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. (2008) (22)
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. (2000) (22)
Antiviral Activity and Safety of Aplaviroc with Lamivudine/Zidovudine in HIV-Infected, Therapy-Naive Patients: The ASCENT (CCR102881) Study (2008) (22)
Biochemical thyroid profile in patients infected with the human immunodeficiency virus. (1991) (22)
THYROID HORMONES IN SERIOUS NON-THYROIDAL ILLNESS (1976) (21)
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. (1996) (21)
Heterosexual promiscuity among African patients with AIDS [letter] (1985) (21)
Update on highly active antiretroviral therapy: progress and strategies. (2000) (21)
Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in a patient with AIDS. (1993) (21)
The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction (2003) (21)
VIRUS-LIKE PARTICLES IN LYMPHOCYTES OF SEVEN CASES OF AIDS IN BLACK AFRICANS (1983) (21)
Corticosteroids as adjunctive therapy for Pneumocystis pneumonia in patients with AIDS. (1991) (21)
Recently diagnosed sexually HIV-infected patients: seroconversion interval, partner notification period and a high yield of HIV diagnoses among partners. (2001) (20)
Thymopentin treatment in aids and pre-aids patients (1985) (20)
Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome. (2001) (19)
Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. (2018) (19)
Feasibility and acceptability of HIV screening through the use of rapid tests by general practitioners in a Brussels area with a substantial African community (2013) (19)
Treatment of diabetic coma with small intravenous insulin boluses. (1976) (18)
STIMULATION OF CELLULAR FUNCTION BY THYMOPENTIN (TP-5) IN THREE AIDS PATIENTS (1983) (18)
FLUCONAZOLE VERSUS KETOCONAZOLE IN OROPHARYNGEAL CANDIDIASIS IN AIDS (1989) (18)
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS. (1997) (18)
Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion (1992) (18)
High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus (2015) (17)
Current use of anti-HIV drugs in AIDS. (1993) (17)
Survival of European patients with Kaposi's sarcoma as AIDS‐defining condition during the first decade of AIDS (1997) (17)
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. (2016) (17)
Seroepidemiological study on sexually transmitted diseases and hepatitis B in African promiscuous heterosexuals in relation to HTLV-III infection (1987) (16)
A Double-Blind , Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R 5 HIV-1 (2009) (16)
Salmonella bacteremia in African patients with human immunodeficiency virus infection (1988) (16)
Antiviral drugs other than zidovudine and immunomodulating therapies in human immunodeficiency virus infection. An overview. (1988) (16)
Absence of antibodies to HIV-2/HTLV-4 in six central African nations. (1987) (16)
Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients (2000) (16)
Single-dose versus 7 days of fluconazole treatment for oral candidiasis in human immunodeficiency virus-infected patients: a prospective, randomized pilot study. (1993) (16)
Safety and Efficacy of Single-Dose Fluconazole Compared with a 7-Day Regimen of Itraconazole in the Treatment of AIDS-Related Oropharyngeal Candidiasis (1998) (14)
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. (1996) (14)
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials. (2010) (14)
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting (2014) (14)
Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993. (1999) (14)
Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms (1983) (13)
Bacterial extract OM85-BV induces interleukin-12-dependent IFN-gamma production by human CD4+ T cells. (1998) (13)
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015 (2017) (13)
Kaposi's sarcoma in patients infected with human virus (HIV): an overview. (1995) (12)
Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. (2007) (12)
Use of hydroxyurea in heavily pretreated patients with HIV infection. (1999) (12)
Acquired resistance to clarithromycin as combined therapy in Mycobacterium avium intracellulare infection (1993) (11)
Limited HIV-1 Reactivation in Resting CD4+ T cells from Aviremic Patients under Protease Inhibitors (2016) (11)
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study (2017) (11)
Anticardiolipin antibodies (ACA) are most often not associated with lupus‐like anticoagulant (LLAC) in human immunodeficiency virus (HIV) infection (1991) (11)
Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe (1991) (11)
A randomized study investigating the efficacy and safety of amprenavir in combination with low‐dose ritonavir in protease inhibitor‐experienced HIV‐infected adults (2004) (10)
Treatment of progressive multifocal leukoencephalopathy (PLM) with Cidofovir in an AIDS patient (1996) (10)
Cefotaxime therapy of serious infections with multiresistant gram-negative bacilli. (1982) (10)
Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy (2017) (10)
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group. (1996) (10)
Long‐term follow‐up of randomized trials of immediate versus deferred zidovudine in symptom‐free HIV infection (1998) (10)
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials (2010) (9)
PREDICTING GENTAMICIN RESISTANCE FROM ANNUAL USAGE IN HOSPITAL (1986) (9)
Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections. (1983) (9)
Call for network of Centres of Excellence in clinical research in Europe (2004) (9)
Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis (1991) (9)
Rapid diagnosis of bacterial meningitis. (1981) (9)
Single cell analysis of antigen-specific T cell responses in HIV-infected individuals. (1999) (9)
Cytomegalovirus retinitis in patients with AIDS in Europe (1997) (9)
Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy. (1998) (8)
Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events. (2014) (8)
ACQUIRED IMMUNE DEFICIENCY SYNDROME IN BELGIUM AND ITS RELATION TO CENTRAL AFRICA a (1984) (8)
The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. (1993) (8)
The role of excess iron in the pathogenesis of disturbed neutrophil functions in cirrhotic patients (neutrophil functions in cirrhotic patients). (1987) (7)
EPIDEMIOLOGY OF MDR-TB IN A BELGIAN INFECTIOUS DISEASES UNIT: A 15 YEARS REVIEW (2013) (7)
SMALL INTRAVENOUS INSULIN BOLUSES IN THE TREATMENT OF DIABETIC COMA (1975) (7)
Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic (2018) (7)
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens (2017) (7)
Gonococcal arthritis-dermatitis syndrome. (1982) (6)
CEFOTAXIME AND NEPHROTOXICITY (1979) (6)
MENINGITIS AND SPLENIC INFARCTION DUE TO DISSEMINATED MYCOBACTERIUM GENAVENSE INFECTION IN AN HIV PATIENT CASE REPORT AND REVIEW OF THE LITERATURE (2013) (6)
[Contribution of the "limulus test" to the diagnosis of endotoxemias and meningitis due to gram negative bacteria]. (1976) (6)
Ritonavir/Saquinavir plus One Nucleoside Reverse Transcriptase Inhibitor (NRTI) versus Indinavir plus Two Nrtis in Protease Inhibitor-Naive HIV-1-Infected Adults (Iris Study) (2000) (6)
A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience (2000) (6)
[Professional fatigue syndrome (burnout) : Part 2 : from therapeutic management]. (2017) (6)
Serum sensitivity of strains isolated and antibodies against O antigen in gram-negative bacteraemia. (1982) (6)
First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial (2014) (6)
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events (2012) (5)
Natural history of HIV infection in African patients (1988) (5)
Viral Load and CD4 response to PI containing regimen in B versus non-B treatment naïve HIV-1 patients (2003) (5)
Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis (1994) (5)
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial) (2020) (5)
MIRO: a randomized trial of maintenance therapy with or whitout protease inhibitors after 4 months of triple or quadruple induction therapy (1998) (5)
Fosamprenavir boosted with a single 100 mg capsule of Ritonavir as part of a once daily first line regimen in naive patients (2006) (5)
Oral “hairy” leucoplakia in an African AIDS patient (1986) (5)
Absence of interaction between Indinavir and Fluconazole, a pharmacokinetic study in HIV patients (1996) (5)
Nutritional status and antiprotease therapy. (1998) (5)
Treatment of acute toxoplasmosis with intravenous clindamycin (1991) (5)
Pharmacokinetics of two multiple dosing regimens of D0870 in HIV positive patients: a phase I study (1995) (5)
Recombinant granulocyte colony-stimulating factor (rG-CSF) in HIV patients with zidovudine related neutropenia. (1992) (5)
Corrigendum to “SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS”[J Hepatol 42 (2005) 615–624] (2005) (5)
Combined quadruple therapy with Ritonavir-Saquinavir+ nucleosides in patients who failed in triple therapy with Ritonavir, Saquinavir or Indinavir (1998) (4)
Acute pulmonary hypertension following paclitaxel in a patient with AIDS-related primary effusion lymphoma. (2001) (4)
The Lubumbashi Trial: Week 48 Data: Comparison between Lopinavir/r (LPV/r) versus Nevirapine (NVP)-based Regimens in Treatment-naïve Patients in a Developing Country (2011) (4)
T-Cell Count Reduces the Risk of Persistent Cervical High-Risk Human Papillomavirus Infection in HIV-Positive Women (2013) (4)
Prospective Collection of Data on the Prevalence of Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in Belgium in 2004 (2004) (4)
Therapeutic approach to mycotic infections in AIDS patients (1991) (4)
The effectiveness of indicator disease-based HIV testing across Europe - results from a prospective multi-centre study (2015) (4)
Analysis of the interferon system in African patients with acquired immunodeficiency syndrome (1985) (4)
Some epidemiological and clinical characteristics of African AIDS. (1987) (4)
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the phase III ECHO and THRIVE trials (2010) (4)
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine. (1999) (4)
Double-blind randomized study of oral Fluconazole versus Ketoconazole in 40 episodes of oropharyngeal cadidiasis in ARC/AIDS patients (1989) (4)
Use of ceftazidime in severe Gram-negative infections--a preliminary study. (1981) (3)
Safe and effective use of combination antiretroviral treatment. (1999) (3)
Virological response with fully active etravirine (ETR; TMC125) after 48 weeks of treatment: pooled results from the DUET-1 and DUET-2 trials (2008) (3)
Virological response to salvage therapy at 6 month in patients with B or non-B subtypes. (2002) (3)
The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group. (1991) (3)
[Severe digestive complications of AIDS in a group of patients from Zaire]. (1984) (3)
Socio-cultural factors in relation to HTLV-III/LAV transmission in urban areas in Central Africa [abstract] (1985) (3)
Occurrence of oral pathology among different risk groups of HIV infected patients (1989) (3)
Fluconazole in the treatment of fungal infections associated with AIDS (1989) (3)
Preliminary results on clinical and immunological effects of thymus hormone preparations in AIDS (1989) (3)
Acquired immuno-deficiency syndrome: a fatal but preventable disease. (1983) (3)
[Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. (1997) (3)
The challenge: streamlining HIV treatment and care while improving outcomes (2014) (3)
Cluster of heterosexual transmission of HIV in Brussels (1987) (3)
Fungal infections in the AIDS patient (1991) (3)
Preliminary results on clinical and immunological effects of thymopentin in AIDS. (1984) (3)
Minimum effective dose and duration to reverse neutropenia in non-cancer patients with advanced HIV disease. (1996) (3)
Prevention of opportunistic infections (2010) (2)
[Acquired immunodeficiency syndrome (AIDS) manifested as severe genital herpes. Apropos of 2 cases]. (1984) (2)
A randomized European trial comparing Pyrimethamine Clindamycine (P/C) to Pyrimethamine Sulfadiazine (P/S) in AIDS toxoplasmic encephalitis (TE) (1992) (2)
Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial (2010) (2)
CD4 response to monotherapy with stavudine in zidovudine experienced patients: lack of correlation of V75T mutation with therapeutical failure (1996) (2)
Clinical and pharmacological evaluation of different preparations of oral erythromycin. (1979) (2)
Bacterial endocarditis, intravascular coagulation and aortic bifurcation embolism. (1976) (2)
A perspective of the history of HAART (2004) (2)
Immunological aspects of severe bacterial sepsis (1981) (2)
507 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV/HIV co-infection: Results from the aids pegasys ribavirin international co-infectio (abstract withdrawn) (2004) (2)
Acquired immune deficiency syndrome in Belgium (1984) (2)
Salvage anti HIV triple therapy with Foscarnet in combination with Nelfinavir and Nevirapine in heavily pretreated patients (1998) (2)
Treatment of Fluconazole resistant oral candidosis with D0870 in patients with AIDS (1994) (2)
Heterosexual transmission of AIDS: No time for complacency (1986) (2)
Limulus test and meningitis. (1977) (2)
Which Lessons Can We Learn from Africa (1988) (2)
Four cases of XDR-Tuberculosis treated with meropem-Clavulanate (2010) (2)
Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study (2006) (2)
Rapidly developing neurological symptoms in a 40-year-old man with AIDS. (1995) (2)
New therapeutic approaches in the acquired immune deficiency syndrome. (1991) (2)
Moxalactam therapy of serious infections (1983) (2)
Pattern of HIV heterosexual infection in Brussels (1988) (1)
Pharmacokinetics of TIBO (R82913) in AIDS patients: a phase I study (1991) (1)
Human immunodeficiency virus infection of the nervous system (1990) (1)
The Sanford guide to antimicrobial therapy 1992 (1992) (1)
, of Aplaviroc ( GW 873140 ) Hepatotoxicity Observed in Clinical Trials (2008) (1)
The debate on HIV Africa (2000) (1)
[Pulmonary manifestations of acquired immunodeficiency syndrome]. (1988) (1)
94 – Opportunistic Infections: Management and Prevention (2017) (1)
Treatment of esophageal cadidiasis with Fluconazole: a prospective study (1990) (1)
Darunavir in patients who failed on fos-amprenavir: efficacy at week 48 (2008) (1)
Efficacy and tolerability of the combination of Lopinavir/Ritonavir and Amprenavir in patients with multiple protease inhibitors resistant HIV strains: results at week 24 (2001) (1)
Infections Invasives à Haemophilus Influenzae (2004) (1)
The rapid evolution of HIV therapy. (2000) (1)
Tuberculosis (TBC) in HIV infected patients (P): A multicentric, randomized comparative study of a three versus a four drug regimen (1992) (1)
Salmonella infections in African patients with AIDS (1985) (1)
Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. (2004) (1)
Clinical and pharmacological evaluation of erythromycin ethylsuccinate in patients with chronic bronchitis (1978) (1)
Synergistic activation of HIV-1 expression by compounds targeting the positive transcription elongation factor b (P-TEFb) and by inducers of the NF-kB signaling pathway (2013) (1)
Sexually-linked clusters of Zairian patients with AIDS suggesting bidirectional heterosexual transmission [abstract] (1985) (1)
Cerebral Toxoplasmosis over the last 10 years in a 2394 patient cohort in Brussels (2000) (1)
Nelfinavir-containing regimen in treatment-naîve HIV-1 patients (pts): comparison of efficacy in B versus non-B subtypes (2002) (1)
Efficacy and safety of Indinavir (IDV) 800 mg BID versus 400 mg BID combined with ritonavir (RTV) 100 mg BID in naïve patients (2002) (1)
Use of granulocyte and granulocyte-lacrophage colony stimulating factors in HIV patients (1991) (1)
Distribution of Human Papillomavirus (HPV) Genotypes in a Cohort of African HIV-positive Women Living in Europe: Estimation of Coverage by Current and Future HPV Vaccines (2013) (1)
[Nevirapine (Viramune): a new HIV inhibitor]. (1999) (1)
A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study (2010) (1)
Observational cohort study of rilpivirine (RPV) utilization in Europe (2022) (1)
Efficacy of pyrimethamine-clindamycine for the long term suppressive therapy of toxoplasmosis encephalitis in AIDS patients (ENTA 04 study) (1994) (1)
STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS * (2005) (1)
[Polymyositis associated with HIV immunodeficiency: clinical case and literature review]. (2001) (1)
Viral and immune response to Nelfinavir-Saquinavir or Ritonavir-Saquinavir, in HIV+ patients heavily pretreated with protease inhibitors (1998) (1)
Patterns of psychiatric and psychosocial hospitalizations of HIV patients (1991) (1)
Acute endocarditis due to Salmonella dublin. (1983) (1)
Current problems in the management of AIDS patients (1988) (1)
Heterosexual Contact Is Not the Predominant Mode of HTLV-III Transmission Among Intravenous Drug Abusers-Reply (1986) (1)
[Septicaemia and spontaneous peritonitis in the cirrhotic (author's transl)]. (1979) (1)
Prevalence of Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in Belgium Prospectively Collected Frim 2003 to 2005 is Significantly Higher Than 5% (2006) (1)
The epidemic of AIDS virus infection, what is the interest for oncologists? (1987) (1)
[Computed tomography aspects of cerebral toxoplasmosis in AIDS]. (1990) (1)
Use of Third-Generation Cephalosporins in Septicemic Burned Patients (1985) (1)
Lactic acidosis complicating diabetic ketosis in a patient with hyperthyroidism. (1977) (1)
Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor–Containing cART Regimens in Antiretroviral-Naïve Patients Starting cART After January 1, 2000 (2006) (1)
European Network for Treatment of AIDS (ENTA) (1995) (1)
Therapeutic vaccination against Hiv-1 in identical twins (1993) (1)
Antimicrobial prophylaxis in HIV-infected adults. (1994) (1)
Atazanavir has a better impact on lipid profiles than Fosamprenavir and Lopinavir in patients matched baseline triglycerides and cholesterol (2006) (1)
The benefit of Zidovudine in the treatment of AIDS patients with cerebral toxoplasmosis (1988) (1)
Fungal infections in AIDS patients (1985) (1)
Infection with high risk Human Papillomavirus (HRHPV) among HIV-positive women: epidemiology, natural history and impact of combined antiretroviral therapy (2014) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Social and human impact of AIDS (1988) (0)
Host factors as a suspected cause for treatment failure with highly active abtiretroviral therapy (HAART) in patients with susceptible HIV-1 isolates: a role for MDR-antigens ? (1998) (0)
[Cefotaxime in the treatment of severe infections due to multiresistant Gram-negative bacilli (author's transl)]. (1981) (0)
Opportunistic infections in aids patients excluding pulmonary infections (1991) (0)
TRICOT: a pilot study on the safety of triple therapy wilt Peginterferon Alfa-2A (40kd), Ribavirine and Amantadine in HIV/HCV co-infected patients (2005) (0)
Cryptococcosis in AIDS (1994) (0)
Efficacy and tolerance of a low dose compared with a standard regimen of Didanosine (ddl): a prospective randomized comparative study (1993) (0)
[Epidemiological and clinical aspects of acquired immunodeficiency syndrome]. (1986) (0)
Virological and immunological effects of Hydroxyurea salvage therapy in HIV infected patients (1999) (0)
Primary HIV infection: Is outcome after treatment interruption influenced by treatment initiation? (2004) (0)
Reactivation of postintegration HIV-1 latency : potential therapeutic approach to purge the viral reservoirs (2014) (0)
TREATMENT AND PREVENTION OF TOXOPLASMIC ENCEPHALITIS (1994) (0)
Treatment of diabetic coma with intravenous insulin boluses. Comparison between 5 IU and 20 IU/hour (1977) (0)
Perspectives in the management of opportunistic infections in HIV-infected patients : the role of granulocyte colony-stimulating factor (1999) (0)
P.411 The impact of age on sustained virological response in genotype 1 HIV-HCV co-infected patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): AIDS PEGASYS ribavirin co-infection trial (APRICOT) (2006) (0)
Predominant production of gamma interferon after a tetanus vaccine booster in healthy controls and HIV-infected patients (1997) (0)
Amoxicillin EntryintoHumanCerebrospinal Fluid: Comparison withAmpicillin (1978) (0)
ICU hospitalization for malaria in a main downtown Brussels hospital: a five year retrospective study (1999) (0)
Clinical and biological experience with Teicoplanin at various dosages in severe Staphylococcus aureus methicillin-resistant septicemia (1987) (0)
ENTA 10: a randomized double blind placebo control study of rifabutine prophylaxis and early diagnosis of tuberculosis and atypical mycobacteriosis in Europe (1998) (0)
Does Very early Initation of HAART in Patients on TB Treatment Provide Benefit in a High Income Setting (2011) (0)
Clinical significance of CMV-DNA detection in peripheral blood leucocytes of AIDS patients (1994) (0)
Epidemiological correlations between African AIDS and AIDS in Europe (1986) (0)
Successful treatment of severe anogenital papillomavirus infections in AIDS patients with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (1995) (0)
Cryptococcal Infection and AIDS (1996) (0)
O001 PREDICTING THE FUTURE OF THE HIV EPIDEMIC: THE DYNAMIC BETWEEN HIGH HAART USAGE AND PREVALENCE OF DRUG-RESISTANT STRAINS OF HIV (2016) (0)
Trastuzumab resistance: Bringing tailored therapy to the clinic (2008) (0)
Nelfinavir versus Indinavir/ritonavir in treatment naive patients: comparison of efficacy and safety at one year. (2002) (0)
Tolerance of pyrimethamine-clindamycine and pyrimethamine-sulfadiazine during acute therapy of toxoplasmosis encephalitis in AIRDS patients in a randmized European multicenter study (1994) (0)
Pathogénèse de l'infection à HIV (1988) (0)
SAFETY OF TOTALLY IMPLANTABLE INTRAVENOUS DEVICE-PORTACATH (PAC) IN HIV PATIENTS (p) (1994) (0)
Single dose versus 7 days Fluconazole for treatment of oral candidiasis in HIV infected patients: a prospective randmized study (1990) (0)
Long-term evaluation of efficacy and tolerance of an extended use of recombinant human erythropoietin in AIDS and ARC patients (1994) (0)
Neurological involvements in African AIDS [abstract] (1985) (0)
[Acquired immunodeficiency syndrome (AIDS) and stomatology]. (1985) (0)
HDAC inhibitors and NF-kB inducers cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. (2005) (0)
Salvage regimen containing meropenem plus clavulanic acid for extensive pulmonary XDR-/pre-XDR-TB: a case-series of 16 patients (2014) (0)
International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK (2014) (0)
Pentosan polysulfate in HIV patients: a phase I study (1990) (0)
Book Review AIDS Therapy Edited by Raphael Dolin, Henry Masur, and Michael S. Saag. 864 pp., illustrated. New York, Churchill Livingstone, 1999. $150. 0-443-07592-1 (1999) (0)
Sustained Viral Suppression and Higher CD4 Cell Count Reduces the Risk of Cervical Infection with High-risk Human Papillomavirus (HR-HPV) in HIV-positive Women (2011) (0)
Project for the decriminalization of euthanasia in Belgium (2000) (0)
Satellite Symposium to the Fifth European Conference on Clinical Aspects and Treatment of HIV Infection: Summary (1995) (0)
Overcoming therapeutic challenges : resistance, intolerance, end-points : satellite symposium to the Fifth European Conference on Clinical Aspects and Treatment of HIV Infection (1995) (0)
Reactivation of HIV-1 gene expression by histone methyltransferase or DNA methylation inhibitors (2011) (0)
HTLV-III infection in African families [abstract] (1985) (0)
Nelfinavir-containing regimen in treatment-naïve HIV-1: comparison of efficacy in B versus non B-subtypes (2002) (0)
Long lasting viral suppression and immune reconstitution of a great magnitude reduce the risk of cervical dysplasia in HIV-positive women (2015) (0)
[AIDS and mucocutaneous lesions]. (1986) (0)
Pattern of hepatotoxicity on different antiretroviral regimens in HIV – patients with or without chronic hepatitis (2005) (0)
Amplification techniques in HIV-Infected patients with smear-negative culture proven pulmonary tuberculosis (2006) (0)
Cefotaxime therapy of serious multi-resistant gram-negative bacillary infections (1980) (0)
Impact of Methadone treatment on medical and addiction treatment compliance during hospitalisation of HIV positive IVDU’s in the Division of Infectious Diseases of University Hospital Saint-Pierre (1995) (0)
Fluconazole in oropharyngeal and oesophageal Cadidiasis (1988) (0)
Long-term safety of Amprenavir (APV) containing regimens in PI naïve patients (2002) (0)
Reactivation of HIV-1 gene expression by DNA methylation or histone methyltransferase inhibitors (2011) (0)
CLINICAL EXPERIENCES WITH “THIRD GENERATION” CEPHALOSPORINS: CEFOTAXIME AND MOXALACTAM IN SEVERE GRAM-NEGATIVE MULTI-RESISTANT INFECTIONS (1981) (0)
Guidelines for the prevention of AIDS – Council of Europe (1987) (0)
Faculty Opinions recommendation of Routine HIV screening--what counts in evidence-based policy? (2011) (0)
Sarcome de Kaposi (1986) (0)
Aspects récents du SIDA. (1991) (0)
Pharmacokinetics ofR 82913inAIDSPatients: a PhaseI Dose-Finding StudyofOralAdministration Compared withIntravenous Infusion (1992) (0)
Resistance testing in HIV-1 infected patients treated with indinavir/ritonavir 800mg/100 mg BID after at least one protease inhibitor-based therapy failure (2002) (0)
[Outpatient management of seropositive patients]. (1993) (0)
[AIDS: the impact of new molecules]. (1999) (0)
Successful treatment of severe relapsing anogenital papillomavirus infections in AIDS patients with (S)-1-(3-Hydroxy-2-phosphonyl methoxypropyl) cytosine (HPMPC) (1995) (0)
Tuberculosis in European HIV patients: Efficacy of three vs four drugs (1995) (0)
Campylobacter species and Other Enteric Pathogens in HIV-Infected Patients (1996) (0)
Initiation of an anal cancer screening in HIV+MSM: results of cytology, biopsy and determination of risk factors (2012) (0)
Therapeutical approaches to HIV infection and related conditions: an updated review. (1990) (0)
UseofCeftazidime intheTherapy ofSerious Infections, Including ThoseDuetoMultiresistant Organisms (1983) (0)
[637] LIPID STEATOSIS, METABOLIC VARIABLES AND BODY COMPOSITION IN THE SETTING OF HIV/HCV COINFECTION; FINDINGS FROM A LARGE RANDOMIZED TRIAL (2007) (0)
High Prevalence and Incidence of Oncogenic Human Papillomavirus (HPV) Infection in a Cohort of African HIV Positive Women in Belgium (2011) (0)
Nelfinavir: 12 month safety and efficacy versus boosted Indinavir, each in combination with 2 Nucleoside Reverse Transcriptase Inhibitors, in treatment naïve patients. (2002) (0)
Causes of death and hospitalisation in the Brussels Saint Pierre Cohort 1998-2005 (2007) (0)
Predictive value of CMV-DNA detection in peripheral blood leucocytes of AIDS patients (1994) (0)
Survival differences inEuropean patients withAIDS,1979-89 (1994) (0)
[Human immunodeficiency virus infection: physiopathological approach to specific therapeutic strategies]. (1996) (0)
Patterns of resistance mutation in B versus (vs) non-B patients (p) with previous PI failure (2004) (0)
Risk Factors for Osteoporosis in HIV Patients Aged 50 Years or More (2013) (0)
HIV-1 subtype determination in routine clinical samples from 5 countries using an internet-based subtyping tool. (2001) (0)
Comparative study of thyroid biochemical abnormalities (TBA) in acquired immunodeficiency syndrome (AIDS) and other illnesses (1989) (0)
Use of anticore glycolipid antibodies in intensive care unit: A preliminary pharmacokinetic study (1985) (0)
LAV/HTLV-III infection in children of African origin: Experience in Belgium (1986) (0)
[Current clinical aspects of AIDS]. (1993) (0)
536Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs) Comparing Initial Non-Nucleoside Reverse-Transcriptase Inhibitor (NNRTI)- versus Ritonavir Boosted Protease Inhibitor (PI/r)-based Anti-Retroviral Therapy (ART) (2014) (0)
R-HU erythropoietin (EPO) in HIV/Zidovudine associated anemia (1991) (0)
HTLV-III/LAV as a likely causative agent of unexplained lymphocytic meningitis in AIDS (1986) (0)
[AIDS: myths, untruths and reality]. (1993) (0)
Single dose Fluconazole versus 7 days Itraconazole for treatment of oral candidiasis in HIV patients: a prospective and randomized study (1993) (0)
Fungal infections in African AIDS (1984) (0)
Multi Drug Resistant Tuberculosis (MDR-TB) in HIV Patients in a High Income Country: Experience in a Belgian HIV Tertiary Center (2013) (0)
[Aspects of the interrelationship between the infected host and the pathogenic agent]. (1983) (0)
Comparison of three HIV-1, RNA quantification assays: NASBA HIV-1 RNA QT, amplicator HIV monitor and quantiplex HIV RNA assay. (1995) (0)
Toxoplasma gondii septicemia without organ involvement in a toxo-seronegative AIDS patient (1996) (0)
started? When should antiretroviral therapy for HIV be (2007) (0)
Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee. (1998) (0)
Open study of Calrythromycin + Paromomycin in severe diarrhoea of unknown or cryptosporidial aetiology in AIDS patients: preliminary results (1996) (0)
Prevalence and clinical presentation of clostridium difficile infection in HIV patients (1990) (0)
Demographic, clinical and Biological profile of HIV infected African patients recruited in a Belgian AIDS Reference Centre between 1997 and 2002 (2004) (0)
Increased prevalence of anti-cyclic citrullinated peptides antibodies (ACPAs) in HIV patients (2013) (0)
A prospective, randomised, placebo-controlled study of the treatment of primary HIV infection with zidovudine (1992) (0)
HTLV-III/LAV antigen prevalence among homosexual and heterosexual patients with HTLV-III/LAV antibodies (1986) (0)
Prevalence of reverse transriptase (RT) and protease (PR) gene mutations in patients followed in a Belgian AIDS Reference Center. (2004) (0)
Hyporeninemic hypoaldosteronism associated with HIV-1 positivity (1989) (0)
The debate on HIV in Africa (multiple letters) (2000) (0)
Cell- associated HIV DNA in semen is low during early stages of primary HIV infection and is efficiently suppressed with HAART (2000) (0)
Impact of HIV treatment on clearance of human papillomavirus (HPV) infection in HIV-infected women (2008) (0)
[Current aspects of AIDS]. (1990) (0)
Disease outcome among heterosexual Africans with HIV infection (1987) (0)
Immunological and virological effects of Hydroxyurea in a cohort of heaviliy pretreated patients (1999) (0)
[Impact of anti-retroviral treatment with protease inhibitors on the evolution of cytomegalovirus retinitis in the patient carrying acquired immunodeficiency syndrome]. (1997) (0)
Avasculas necrosis (AVN) in HIV-infected patient treated with highly active antiretroviral therapy (HAART) (2000) (0)
[Professional fatigue syndrome (burnout). Part 1 : identification by the general practitioner]. (2017) (0)
Analysis of questions and problems presented by HIV-Infected persons in sexological consultation (1998) (0)
Perspectives for the treatment of human papillomavirus infections (1995) (0)
Tuberculosis in HIV infected patients: A multicentric, randomized comparative study of a three versus four drug regimen (1993) (0)
AIDS in Africa. (1989) (0)
Severe adverse events in patients receiving Rifabutin low dose and Ritonavir baby dose (2000) (0)
Manifestations pulmonaires au cours de l’infection à VIH (1989) (0)
Publications - Division of Infectious Diseases & Hospital Epidemology 2005 (2005) (0)
[Management and treatment of patients infected with the. "pandemic A/H1N1 2009 influenza virus" in a hospital milieu]. (2009) (0)
Zidovudine (ZDV) but not didanosine (ddl) improves HIV related thrombocytopenia (HIV-TCP) in patients with ZDV resistant strains (1994) (0)
Impact of protease inhibitors on the evolution of cytomegalovirus retinitis in AIDS patients (1998) (0)
Ten years follow-up of patients starting protease inhibitor with CD4 below 100/µl: The Picasso Cohort (2007) (0)
Calcaneal Stiffness Index to Screen for Osteoporosis in HIV Patients: A Valuable Tool? (2013) (0)
Clinical Impact of a prospective Policy of Methicillin-Resistant Staphylococcus aureus (MRSA) Carrier Screening in a Medical Intensive Care Unit (mICU) (2001) (0)
The contribution of the 67-Ga scintigraphy in the evaluation of AIDS (1990) (0)
HIV infection: from the pathophysiological approach to specific therapeutic interventions. (1996) (0)
Virological and immunological response to HAART in Africans versus Caucasians naïve HIV patients (2003) (0)
Epidemiology of Multi Drug Resistant Tuberculosis (MDR-TB) in a Belgian Infectious Diseases Unit: a 15 year review (2011) (0)
Attitudes and opinions toward HIV infection of 1,008 participants to the Vth International Conference on AIDS Montreal, 4-9 June 1989. (1990) (0)
Rifabutin versus rifampin in the treatment of tuberculosis in HIV patients (2005) (0)
[Current aspects of AIDS]. (1991) (0)
Randomized comparative study of Teicoplanin (Te) and Vancomycin (Van) in severe S. aureus Methicillin-resistant (Me-R) infections (1986) (0)
Histological response to pegIFNα-2a (40ΚΔ) plus ribavirin in ΗΙ-hepatitis C virus co-infection. Commentary (2006) (0)
Response to boosted-saquinavir (SQV) containing HAART in PI-experienced patients: comparison of B versus non-B subtypes (2003) (0)
Abnormal T4 molecule expression of helper/inducer T lymphocytes in African AIDS patients. (1984) (0)
Aspects geographiques du syndrome d'immunodeficience acquise. (1986) (0)
P03/04 Socio-demographical and Behavioral Characteristics of Sub-Saharan Africans ( SSA) At-tending a Voluntary and testing (VCT) Centre in Brussels (2014) (0)
Other Cases Presented by the Department of Dermatology (1982) (0)
Antimicrobial agents: viral/parasitic: Editorial overview (1992) (0)
Seroepidemiology of sexually transmitted diseases in African promiscuous heterosexuals: its relation to HTLV-III infection (1985) (0)
Reversal of thrombocytopenia and leucopenia in HIV patients with CD4 cells count below 50 treated with protease inhibitors (1997) (0)
Detection of Mycobacterium tuberculosis infection in HIV-infected patients. (2012) (0)
Reactivation of HIV-1 gene expression by histone methyltransferase inhibitors of DNA methylation inhibitors (2011) (0)
The Prevalence and profiles of patients who practice religion and prayer at an AIDS reference center in Brussel (2004) (0)
Clinical care and multidisciplinary management of HIV patients (1991) (0)
One year experience of Azidothymidine (AZT) administrered 6 hourly in 40 patients with AIDS ir AIDS related complex (1988) (0)
Cutaneous adverse events with abacavir and NNRTI combination: benefit of a delayed introduction of NNRTI (1999) (0)
Keynote Address: Heterosexual Transmission: Fear or Reality (1986) (0)
[Heterosexual transmission of AIDS]. (1989) (0)
Genotypic and phenotypic sensitivity of viral isolates, in patients failing to AZT-3TC-141W94 (1998) (0)
HDAC inhibitors and the NF-B inducer prostratin cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs (2007) (0)
Filgrastevi has differential effects on neutropffll (PMN) transduction pathways: results of randomized study en non-neutropenic HTV-infected patients (PTS) (2001) (0)
Immunization with recombinant TAT (R-TAT) toxoid vaccine does not prevent viral rebound after treatment interruption (2003) (0)
Anomalies de l’axe renine-aldosterone associées à l’infection par le virus HIV-1 (1988) (0)
Zidovudine but not didanosine improves HIV related thrombocytopenia in patients with ZDV resistant strains (1994) (0)
Efficacy and tolerability of a low dose of Didanosine (DDI): a prospective randomized trial (1992) (0)
Computed tomography of brain toxoplasmosis in AIDS patients (1990) (0)
LE CEFOTAXIME: TRAITEMENT DES INFECTIONS SEVERES PAR BACILLES A GRAM NEGATIF MULTIRESISTANTS (1981) (0)
[Hospital epidemic due to Stpahylococcus aureus resistant to oxacillin and aminoglycosides]. (1984) (0)
Ritonavir-saquinavir rescue therapy in HIV-positive patients failing with indinavir, rotinavir or saquinavir. (1999) (0)
Rapid Progression of a hepatic lesion due to echinococcus multilocularis in an HIV+ patient (1995) (0)
Daily Dapsone versus phyrimethamine-Sulfadoxine (Fansidar ®) as primary prophylaxis against Pneumocystis carinii pneumonia (1991) (0)
Update on ENTA 10, an ongoing study on Rifabutin prophylaxis and early diagnosis of mycobacterial infection in HIV infected patients with CDA ≤ 200 cells/µl (1997) (0)
Urban sexuality: changing patterns in Central Africa. Social determinants of HTLV-III transmission. (1986) (0)
Virological and clinical follow up of HIV patients: Is there any correlation? (1994) (0)
A randomised clinical trial comparing a ritonavir/saquinavir (RTV-SQV) versus an indinavir (IDV) containing triple therapy regimen (IRIS study) (1998) (0)
TRICO: a pilot study on the safety of triple therapy with pegylated interferon + ribavirine + amantadine in HIV/HCV co – infected patients (2004) (0)
Standardizing EU investigate sites (2005) (0)
Nosocomial legionellosis associated with hospital cooling towers contamination (2002) (0)
Humoral immunity in critically ill patients. Therapeutic perspectives. (1983) (0)
141W94-AZT-3TC association:: a novel protease inhibitor added to long-standing AZT-3TC of combined with new reverse transcriptase inhibitors (1998) (0)
[The struggle against AIDS: between new paradigms and inertia]. (2010) (0)
[Cirrhosis and endotoxemia. Clinical significance]. (1979) (0)
In patients failing Haart, patterns of PI and RT mutations differ in B versus non-B subtypes (2001) (0)
Comparison of the efficacy and safety of three PI based regimens in naïve patients: nelfinavir 1250 bid of indinavir/ritonavir 800/100 mg bid versus 400/100 bid (2002) (0)
Contents, Vol. 25, 1979 (1979) (0)
T-CELL DEFICIENCY IN AN AFRICAN FAMILY (1984) (0)
Combination therapy with r-HuEPO and colony-stimulating factors for haematological abnormalities associated with HIV infection (1995) (0)
Severe acute HIV encephalitis after interruption of HAART: a case for caution (2001) (0)
[Value and limitations of vaccines]. (1985) (0)
Contribution of PPD/HBHA Interferon-gamma Release Assay for the Detection of Mycobacterium tuberculosis Infection in HIV Infected Patients (2013) (0)
[Defibrination syndrome during acute pancreatitis: 6 cases. Prospective studies of coagulation in 41 patients (author's transl)]. (1979) (0)
Salmonella typhi (S.typhi) as a common causative agent of pancreatic disturbances (1990) (0)
A randomised study of two cotrimoxazole doses in primary prophylaxis against PCP and cerebral toxoplasmosis (1996) (0)
Picasso: a randomized comparative outcome trial of indinavir and ritonavir in protease inhibitors naiv HIV patients with CD4 below 100 cells/µl (1998) (0)
Disease outcome among heterosexual Africans with HTLV-III/LAV infection (1986) (0)
Comparison of ritonavir and indinavir in HIV patients with advanced disease: a Belgian outcome trial (1996) (0)
High prevalence of anal dysplasia in a cohort of HIV-positive MSM enrolled in a systematic screening programme: risk factors and impact of cART (2013) (0)
HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico (2016) (0)
Epidemiological and clinical aspects of acquired immunodeficiency syndrome (AIDS) (1986) (0)
P03/06 Socio-demographical and Behavioral Characteristics of Men who Have Sex with Men (MSM) Attending a Voluntary Counseling and testing (VCT) centre in Brussels (2014) (0)
High prevalence of co-infection with HIV and HCV in heterosexuals in Belgium: comparison with other transmission groups. (2001) (0)
Discontinuation of therapy after treatment for primary HIV infection (PHI) (1999) (0)
8th European Congress of Clinical Microbiology and Infectious Disease, Lausanne, Switzerland, 27 May 1997: Perspectives in the management of opportunistic infections in HIV-infected patients. The role of granulocyte colony-stimulating factor. Introduction (1999) (0)
Characteristics of Men who Have Sex with Men (MSM) Attending an HIV Voluntary Counselling and Testing (VCT) Centre in Brussels and Impact of Anonymous Testing (2013) (0)
PAN-NUCLEOSIDE AND NONNUCLEOSIDE RESISTANT STRAINS AFTER SEQUENTIAL THERAPY WITH NRTIS AND NNRTI (1995) (0)
A comparative outcome trial of ritonavir and indinavir in HIV patients with CD4 cell count below 50 (1997) (0)
Recommendations and directives on the use of cephalosporins and aminoglycosides. (1982) (0)
Fakt: a randomised 48-week trial on impact on lipid parameters of lopinavir/r versus Fosamprenavir boosted with a single 100mg ritonavir capsule (2009) (0)
Impact of physician counseling and support to patients in the routine clinic setting at and AIDS reference center in Brussels (2004) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
Un vitro effect of Clindamycin on polymorphonuclear leucocyte phagocytic and bactericidal function against Staphylococcus aureus in diabetic patients (1991) (0)
A phase II study of Carrisyn (Acemannan) alone and with AZT among symptomatic and asymptomatic HIV patients (1990) (0)
Herpes type II (HSV2): a possible cofactor of the HIV infection among Central African heterosexual patients (1987) (0)
Tuberculosis in HIV patients: Correlation between natural history, clinical presentation and immunological status (1989) (0)
Salvage therapy with Ritonavir-Saquinavir plus 2 nucleosides reverse transcriptase inhibitors in patients failing with Amprenavir-AZT-3TC (1998) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nathan N. Clumeck?

Nathan N. Clumeck is affiliated with the following schools:

Vrije Universiteit Brussel

Nathan N. Clumeck's Academic­Influence.com Rankings